Get the Stockscreener App
15.84
0.96%
0.14
Keros Therapeutics Inc stock is traded at $15.84, with a volume of 18,627.
It is up +0.96% in the last 24 hours and up +1.21% over the past month.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
See More
Previous Close:
$15.70
Open:
$15.72
24h Volume:
18,627
Relative Volume:
0.04
Market Cap:
$643.35M
Revenue:
-
Net Income/Loss:
$-168.05M
P/E Ratio:
-3.0877
EPS:
-5.13
Net Cash Flow:
$-146.15M
1W Performance:
+1.47%
1M Performance:
+1.21%
6M Performance:
+30.13%
1Y Performance:
-73.49%
1-Day Range:
$15.70
$15.93
1-Week Range:
$15.50
$16.44
52-Week Range:
$9.12
$72.37
Keros Therapeutics Inc Stock (KROS) Company Profile
Name
Keros Therapeutics Inc
Sector
Industry
Phone
617-314-6297
Address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
15.84 | 637.66M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.50 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.52 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
543.83 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
795.93 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-21-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-17-25 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-16-24 | Reiterated | Oppenheimer | Outperform |
| Dec-13-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-12-24 | Downgrade | BTIG Research | Buy → Neutral |
| Dec-12-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-12-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-05-24 | Initiated | Jefferies | Buy |
| Oct-24-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-23-24 | Initiated | Guggenheim | Buy |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Feb-21-24 | Initiated | William Blair | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jul-31-23 | Initiated | Wedbush | Outperform |
| Jul-26-23 | Initiated | BofA Securities | Buy |
| Feb-14-23 | Initiated | Cowen | Outperform |
| Oct-18-22 | Initiated | Truist | Buy |
| Jul-26-22 | Initiated | BTIG Research | Buy |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| May-04-20 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| May-04-20 | Initiated | SVB Leerink | Outperform |
View All
Keros Therapeutics Inc Stock (KROS) Latest News
Forecasting Keros Therapeutics Inc. price range with options data2025 Top Gainers & Technical Pattern Based Signals - newser.com
How to recover losses in Keros Therapeutics Inc. stock2025 Risk Factors & Weekly Setup with ROI Potential - newser.com
Can trapped investors hope for a rebound in Keros Therapeutics Inc.Long Setup & Consistent Growth Stock Picks - newser.com
Can volume confirm reversal in Keros Therapeutics Inc.2025 Price Action Summary & Intraday High Probability Setup Alerts - newser.com
What analysts say about Keros Therapeutics Inc stockPrice Support Zones & High Yield Trading Signals - earlytimes.in
Keros Therapeutics Inc. stock daily chart insightsMarket Volume Summary & Long Hold Capital Preservation Tips - newser.com
Published on: 2025-10-10 05:54:47 - newser.com
Weiss Ratings Reaffirms "Sell (D)" Rating for Keros Therapeutics (NASDAQ:KROS) - MarketBeat
Investors in Keros Therapeutics (NASDAQ:KROS) have unfortunately lost 72% over the last year - Yahoo Finance
Can machine learning forecast Keros Therapeutics Inc. recoveryPortfolio Value Summary & Expert Verified Movement Alerts - newser.com
Public Employees Retirement System of Ohio Purchases Shares of 26,103 Keros Therapeutics, Inc. $KROS - MarketBeat
Can Keros Therapeutics Inc. recover in the next quarterMarket Performance Recap & Growth Oriented Trading Recommendations - newser.com
Can Keros Therapeutics Inc. rally from current levelsGap Down & Weekly Market Pulse Alerts - newser.com
Will Keros Therapeutics Inc. bounce back from current supportQuarterly Earnings Report & Long-Term Capital Growth Strategies - newser.com
How to interpret RSI for Keros Therapeutics Inc. stockWeekly Stock Summary & Proven Capital Preservation Methods - newser.com
Quantitative breakdown of Keros Therapeutics Inc. recent moveTake Profit & Risk Controlled Stock Pick Alerts - newser.com
Is Keros Therapeutics Inc. stock poised for growthTrade Analysis Report & Growth Oriented Trade Recommendations - newser.com
What momentum indicators show for Keros Therapeutics Inc. stockWeekly Risk Report & Verified Entry Point Signals - newser.com
Keros Therapeutics Inc Stock Analysis and ForecastHigh Yield Income Stocks & Low Entry Cost Investment - earlytimes.in
Is Peeti Securities Limited Positioned to Benefit From Geographic ExpansionSector Performance Review & Achieve Triple Digit Returns - earlytimes.in
Is Keros Therapeutics Inc a good long term investmentEconomic Indicators Overview & Affordable Market Investment - earlytimes.in
What drives Keros Therapeutics Inc stock priceContrarian Investment Ideas & Today’s Picks, Tomorrow’s Winners - earlytimes.in
Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting - ADVFN
Keros Therapeutics Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
Assenagon Asset Management S.A. Purchases 36,360 Shares of Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics: A Potential Dart Throw (NASDAQ:KROS) - Seeking Alpha
TGF-β Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Is now a turning point for Keros Therapeutics Inc.Watch List & Reliable Price Breakout Alerts - newser.com
Keros Therapeutics Inc Stock (KROS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Keros Therapeutics Inc Stock (KROS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 10% Owner |
Apr 09 '25 |
Buy |
10.13 |
934,258 |
9,464,512 |
4,392,737 |
| Seehra Jasbir | CHIEF EXECUTIVE OFFICER |
Apr 04 '25 |
Option Exercise |
0.30 |
49,367 |
14,810 |
302,223 |
2.81%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):